In a recent Q&A with European Biopharmaceutical Review, Stephen Corson—Associate Director of Statistics and Technical Solutions and Head of Statistical Consultancy at Phastar—shared expert insights on the strategic decisions that biotechs must make to ensure successful drug development. A key focus of the discussion was the importance of selecting the right biotech solutions provider and how partnering with a specialist contract research organization (CRO) can deliver significant advantages for emerging biopharma companies.
